Aglietta M - Search Results

1

A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy.

Sottile A, Ortega C, Berruti A, Mangioni M, Saponaro S, Polo A, Prati V, Muto G, Aglietta M, Montemurro F. Sottile A, et al. Among authors: aglietta m. Oncol Lett. 2012 Apr 1;3(4):819-824. doi: 10.3892/ol.2012.570. Epub 2012 Jan 16. Oncol Lett. 2012. PMID: 22741000 Free PMC article.

2

Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.

Montemurro F, Choa G, Faggiuolo R, Sperti E, Capaldi A, Donadio M, Minischetti M, Salomone A, Vietti-Ramus G, Alabiso O, Aglietta M. Montemurro F, et al. Among authors: aglietta m. Am J Clin Oncol. 2003 Feb;26(1):95-7. doi: 10.1097/01.COC.0000017087.19671.05. Am J Clin Oncol. 2003. PMID: 12576933 Clinical Trial.

3

Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy.

Martincich L, Montemurro F, Cirillo S, Marra V, De Rosa G, Ponzone R, Aglietta M, Regge D. Martincich L, et al. Among authors: aglietta m. Radiol Med. 2003 Jul-Aug;106(1-2):51-8. Radiol Med. 2003. PMID: 12951551 English, Italian.

4

Trastuzumab-based combination therapy for breast cancer.

Montemurro F, Valabrega G, Aglietta M. Montemurro F, et al. Among authors: aglietta m. Expert Opin Pharmacother. 2004 Jan;5(1):81-96. doi: 10.1517/14656566.5.1.81. Expert Opin Pharmacother. 2004. PMID: 14680438 Review.

5

Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.

Martincich L, Montemurro F, De Rosa G, Marra V, Ponzone R, Cirillo S, Gatti M, Biglia N, Sarotto I, Sismondi P, Regge D, Aglietta M. Martincich L, et al. Among authors: aglietta m. Breast Cancer Res Treat. 2004 Jan;83(1):67-76. doi: 10.1023/B:BREA.0000010700.11092.f4. Breast Cancer Res Treat. 2004. PMID: 14997056

6

A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.

Montemurro F, Choa G, Faggiuolo R, Donadio M, Minischetti M, Durando A, Capaldi A, Vietti-Ramus G, Alabiso O, Aglietta M. Montemurro F, et al. Among authors: aglietta m. Oncology. 2004;66(1):38-45. doi: 10.1159/000076333. Oncology. 2004. PMID: 15031597 Clinical Trial.

7

Selected highlights from the 26th San Antonio Breast Cancer Symposium. December 3-6, 2003, San Antonio, TX, USA.

Montemurro F, Aglietta M. Montemurro F, et al. Among authors: aglietta m. Expert Opin Pharmacother. 2004 Apr;5(4):981-9. doi: 10.1517/14656566.5.4.981. Expert Opin Pharmacother. 2004. PMID: 15102581

8

HER2 and central nervous system metastasis in patients with breast cancer.

Montemurro F, Sarotto I, Casorzo L, Pisacane A, Aglietta M, De Rosa G. Montemurro F, et al. Among authors: aglietta m. Clin Breast Cancer. 2004 Aug;5(3):232-4. doi: 10.3816/cbc.2004.n.027. Clin Breast Cancer. 2004. PMID: 15335457

9

The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.

Montemurro F, Aglietta M. Montemurro F, et al. Among authors: aglietta m. Cancer. 2005 Mar 15;103(6):1314-5; author reply 1315. doi: 10.1002/cncr.20889. Cancer. 2005. PMID: 15674855 Free article. No abstract available.

10

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation.

Valabrega G, Montemurro F, Sarotto I, Petrelli A, Rubini P, Tacchetti C, Aglietta M, Comoglio PM, Giordano S. Valabrega G, et al. Among authors: aglietta m. Oncogene. 2005 Apr 21;24(18):3002-10. doi: 10.1038/sj.onc.1208478. Oncogene. 2005. PMID: 15735715

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

470 results

Search Page

Filters